东京烘焙职业人每周准时摘取烘焙行业最重要的、最有价值的新品信息、品牌资讯，行业热文和海 外信息，一切你想知道的，都在这里。 在这里不需要恰饭，只需要更新鲜的资讯！ 1、 泽田本家【像素莓莓铜锣烧】 2、糕材生【鸭子的奶面包】 3、PantrysBest派悦坊【荔枝话梅蛋糕】 4、崎本的店【可丽饼吐司】 5、罗森尼娜【心太软面包】 6、祐禾【黑胡椒香肠丹麦棒】 7、面包工坊【冰皮慕斯】 8、 仟吉KenGee 【柠檬柚子味冰戚风】 9、谷古面包【莓完莓了巴斯克】 10、 孙北北面包【青柠芝士蛋糕】 11、爱立颂alissant【女王魔法棒】 12、莱噢【香蕉牛乳卷】 13、 石头先生的烤炉 【SUSU号角】 14、85度C【黄金香薰鸡肉三明治】 15、 COVA【Glam椰子百香果蛋糕】 16、Holiland好利来【芝士麻薯团】 17、 爸爸糖 【开心橙橙冰吐司】 18、 Hibake【夏日出桃】 19、 蒲公英【巧克力瑞士卷】 1、全家FamilyMart 【老式鸡腿形面包】 2、大润发【冰淇凌小蛋糕】 3、罗森【茉莉季新品】 4、叮咚买菜【Gelato 沙布蕾系列】 5、盒马【玫瑰荔枝拿破仑酥】 6、 轩 ...

Core Insights - Full Alliance Group Inc. and its subsidiary Aquaox Pure Solutions have achieved significant regulatory milestones, positioning the company as a leading partner in the hypochlorous acid sector, which is part of the growing $2.8 billion clean beauty market [1][12] - The completion of third-party Human Repeat Insult Patch Testing and FDA MOCRA registration for Aquaox's HOCl products aligns with increasing consumer demand for non-toxic personal care solutions, with 73% of consumers seeking products free from harsh chemicals [2][12] - Aquaox's proprietary nanobubble HOCl technology addresses industry challenges such as product stability and shelf-life, facilitating wider adoption of HOCl products [4][10] Market Opportunities - Aquaox targets three high-growth verticals: the $13.2 billion clean beauty market, which is growing at a 9.7% CAGR; the $4.2 billion infection prevention market; and the e-commerce sector, where 67% of beauty purchases are influenced by social media [5][6][12] - The company's flagship product, JusSpray™, serves as both a revenue generator and proof of market acceptance for advanced hypochlorous formulations [7][8] Competitive Advantages - Aquaox's vertically integrated approach, encompassing proprietary technology, FDA-compliant manufacturing, and direct consumer sales, creates multiple revenue streams and competitive advantages [8][9] - The company is positioned as a leader in the emerging HOCl category, addressing regulatory scrutiny and consumer demand for safer alternatives to traditional antiseptics [9][10] Industry Growth - The hypochlorous acid market is projected to reach $6.852 billion by 2025, with a CAGR of approximately 5.9% from 2025 to 2033, driven by consumer awareness of its safety and efficacy [11][12]

Core Insights - Daré Bioscience, Inc. has received a $6 million non-dilutive funding installment, increasing total funding to approximately $37.8 million out of a potential $49 million for the development of DARE-LARC1, a contraception-focused application of its intelligent drug delivery system [1][10] - DARE-LARC1 is a preclinical-stage long-acting reversible contraceptive utilizing a programmable drug delivery device to administer levonorgestrel, with broader applications in various chronic conditions [2][6] - The DARE-IDDS platform, originally developed at MIT, has been enhanced by Daré to improve its functionality and is capable of delivering multiple doses over extended periods without the need for recharging or surgical replacement [3][4] Funding and Development - The recent funding milestone will support the advancement of DARE-LARC1 and the development of a versatile drug delivery platform across high-value therapeutic areas [3][10] - Daré is eligible for additional non-dilutive funding of up to approximately $11.2 million, contingent on achieving specified technical milestones [10] Market Potential - The DARE-IDDS platform has potential applications beyond reproductive health, including obesity, diabetes, and other chronic conditions, which could significantly improve patient adherence and reduce healthcare costs [6][7] - The platform's features include precision dosing, extended duration of action, and remote programmability, making it suitable for various therapeutic areas [9] Strategic Partnerships - Daré is actively exploring strategic partnerships to expand the evaluation of the DARE-IDDS platform into additional therapeutic categories [2][10] - The company aims to leverage its innovative technology to address unmet needs in women's health and enhance treatment options [11]

ZELSUVMI is now commercially available via prescription through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmaciesOnce-daily topical prescription medication can be applied by patients, parents and caregivers outside of a physician's office, at home or on the goMolluscum contagiosum is a highly contagious viral skin condition that afflicts an estimated 16.7 million people with up to 6 million new incidents per year in the United States, most of them children DURH ...

JUPITER, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE American: PTHS) has commercially launched ZELSUVMI™ (berdazimer) topical gel 10.3%, the first and only FDA-approved at-home treatment for molluscum contagiosum. The Company has earned a $5 million milestone payment from Pelthos following the commercial launch of ZELSUVMI. “Molluscum impacts millions of people in the U.S., particularly children. ...

苏州永沁泉智能设备有限公司（EFL） 创始人，浙江大学 求是特聘教授 贺永 将出席 2025（第四 届）高分子3D打印材料高峰论坛 （7月18-20日 | 浙江 · 杭州），并分享 "生物3D打印：从器官模 型构建到器官体外再造" 。 同时， EFL 将在现场展示 体积光固化生物3D打印机、多功能挤出式生物3D打印机、投影式光固 化生物3D打印机、微针制造仪、甲基丙烯酰化明胶（GelMA）。 EFL围绕再生医学开展"科普→服务研究→助力转化" 全环节服务。 EFL通过打造 生物材料 和 生物制造 两大技术平台，为追求可靠高效的再生医学研究人员提供生物 医用水凝胶、加工与操控设备、监测与分析仪器等整体解决方案，为再生医学研究到转化全环节高效 赋能。 EFL提供以下产品： 01︱ 体积光固化生物3D打印机 主要功能： 可满足载细胞水凝胶结构的快速成形，使细胞与生物组分保持活性。4K的投影精度可满足绝大部分 生物模型的构建需求，光源波段支持定制；5~50℃的材料预处理模块可快速得到可打印的墨水状 态；丰富组织模型库包括上百种生物打印常用模型，免除建模烦恼。 技术亮点： 打印速度快，几十秒即可成型；具备墨水自支撑的特 ...

Core Insights - Glaukos Corporation (GKOS) reported a record-breaking first-quarter 2025 performance with revenues of $106.7 million, a 25% year-over-year increase, primarily driven by the adoption of the iDose TR implant [1][8] - The company reaffirmed its full-year revenue guidance of $475-$485 million, indicating confidence in its commercial momentum [1] Near-Term Growth Drivers - The iDose TR launch is gaining traction, with U.S. glaucoma sales increasing by 41% year-over-year, contributing nearly $21 million in the first quarter, reflecting an $85 million annualized run rate [3] - Internationally, Glaukos achieved $29 million in interventional glaucoma sales, a 15% year-over-year increase, supported by the growing acceptance of minimally invasive glaucoma surgery (MIGS) [4] Long-Term Growth Catalysts - Glaukos has a robust R&D pipeline with key programs including Epioxa, iDose Trex, PRESERFLO MicroShunt, and GLK-401, which are expected to broaden the company's addressable market in the next three to five years [5][6] - The company is cultivating standalone use of MIGS devices like iStent infinite, anticipating long-term growth as more surgeons adopt interventional glaucoma practices [7] Challenges and Watchpoints - Reimbursement complexities and LCD restrictions are impacting legacy stent sales, which declined mid-single digits in the first quarter, with expectations of continued pressure through 2025 [8][9] - Sales of Photrexa remain muted due to the Medicaid Drug Rebate Program, with near-term growth in this segment expected to be flat to low-single digits [10] Competitive Landscape - The iDose TR launch positions Glaukos ahead in procedural glaucoma drug delivery, but competition from Alcon, Johnson & Johnson, and Sight Sciences remains significant [11] - Year-to-date, Glaukos shares have declined by 31.7%, underperforming its rivals in the MIGS space, while Alcon and J&J have seen increases [12]

客户聚焦：双平台激发跨行业场景创新 盛夏香江，智慧激荡。近日，亚太顶级营销科技盛会MarTech HK Summit 2025在香港 丽兹卡尔顿酒店 圆满落幕。本届峰会云集汇丰银行 (HSBC)、星展银 行(DBS)、雅虎(Yahoo)、国泰航空、港铁等数百家企业高管，共探智能营销前沿趋势。领先的客户互动和营销科技服务商，极光(Aurora Mobile，纳斯达 克股票代码：JG) 以"双引擎"阵容重磅亮相——AI智能体平台GPTBots.ai(以下简称"GPTBots") 与EngageLab领先的多渠道互动平台协同展示，成为全场焦 点。 双核展示：AI交互+精准触达，打造增长闭环 本次展会中，极光在香港市场并机呈现两大核心解决方案，GPTBots助力企业用AI提效，EngageLab攻克精准触达难题，两者协同为企业构建从客户洞察 到价值转化的完整闭环。 GPTBots：企业级AI智能体平台 零代码构建专属AI助手，覆盖智能客服、流程自动化、知识管理等高价值场景，驱动业务效率革命。 EngageLab：全渠道智能用户互动平台 整合邮件、短信、APP推送、社交媒体等20+触达通道，通过用户行为分析实现精准自动 ...

CALGARY, Alberta, July 08, 2025 (GLOBE NEWSWIRE) -- Black Diamond Group Limited (“Black Diamond” or the "Company”) (TSX: BDI, OTCQX:BDIMF), a leading provider of space rental and workforce accommodation solutions, today announces the timing of its 2025 second quarter earnings release and conference call/webcast. Black Diamond intends to release its 2025 second quarter results after markets close on Thursday, August 7, 2025, and hold a conference call and webcast at 9:00 a.m. MT (11:00 a.m. ET) on Friday, Au ...

Core Viewpoint - BAB, Inc. reported a decrease in revenues for the second quarter and the first half of 2025, primarily due to a reduction in marketing fund expenses, while net income showed a slight increase compared to the previous year [2][3]. Financial Performance - For the quarter ended May 31, 2025, BAB, Inc. had revenues of $808,000, down 8.4% from $882,838 in the same quarter last year. Net income was $154,000, an increase of 5.9% from $145,685 [2][9]. - For the six months ended May 31, 2025, revenues totaled $1,566,000, a decrease of 8.9% from $1,718,772 in the same period of 2024. Net income rose to $271,000, up 10.8% from $244,190 [3][9]. Operating Expenses - Total operating expenses for the quarter were $608,000, down 12.7% from $696,388 in 2024. The decrease was mainly due to a reduction in marketing fund expenses by $80,000 and other cost reductions [4][9]. - For the six months ended May 31, 2025, total operating expenses were $1,218,000, a decrease of 13.7% from $1,410,342 in the same period of 2024, with marketing expenses accounting for a significant portion of the decline [4][9]. Revenue Breakdown - Royalty fees from franchised stores for the quarter were $511,879, a slight decrease of 0.3% from $513,474 in the previous year. Franchise and area development fee revenue dropped significantly by 61.1% to $3,583 [9]. - Marketing fund revenue decreased by 26.0% to $227,049 for the quarter and by 21.5% to $444,095 for the six months [9]. Earnings Per Share - Earnings per share for the quarter remained stable at $0.02, while for the six months, it increased to $0.04 from $0.03 in the previous year [2][3][9]. Company Overview - BAB, Inc. franchises and licenses several brands including Big Apple Bagels®, My Favorite Muffin®, SweetDuet® frozen yogurt, and Brewster's® Coffee. The company's stock is traded on the OTCQB under the symbol BABB [5].